Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728786 | 0.85 | HDAC6 (0.67) | HDAC6NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1059693 | 0.84 | RAB9A (0.64) | HDAC6NPC1RAB9ASMN1; SMN2LMNA | |
| Water SCHEMBL23043360 | 0.84 | HDAC6 (0.65) | HDAC6NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL757031 | 0.82 | RAB9A (0.62) | HDAC6NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL30037937 | 0.82 | RAB9A (0.62) | HDAC6NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4485011 | 0.82 | MAPT (0.68) | HDAC6NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17933568 | 0.81 | MAPT (0.70) | HDAC6NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL14050118 | 0.81 | MAPT (0.76) | HDAC6NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL103809 | 0.81 | RAB9A (0.60) | HDAC6NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL2929122 | 0.81 | MAPT (0.66) | HDAC6NPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111635365-A | Mixed-valence copper (I, II) complex and in-situ synthesis method thereof | 梧州学院 | 2020-09-08 | — | — | CN | claimed |
| EP-2970328-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-04-26 | — | — | EP | claimed |
| CN-105225779-A | A kind of cobalt-based single-chain magnets and synthetic method thereof | UNIV GUANGXI | 2016-01-06 | — | — | CN | claimed |
| US-9200005-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-01 | — | — | US | claimed |
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | claimed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | MAVERIX ONCOLOGY, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116507326-A | Compounds as GLP-1R agonists | 拓臻制药公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| WO-2000060043-A1 | COMPOSITION AND METHOD FOR BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2000-10-12 | — | — | WO | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| WO-2000023449-A1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| US-5149700-A | Antiarrhythmic agent | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-22 | — | — | US | disclosed |
| WO-1991018904-A1 | SUBSTITUTED ARYLSULFONAMIDES AND BENZAMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | PDE5A, PDE3A, PDE3B | HDAC6 612/4885NPC1 2156/4885RAB9A 625/4885 |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | HDAC6 1432/4885NPC1 690/4885RAB9A 737/4885 |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | ZYX, SLC7A5, GMPS | HDAC6 630/4885NPC1 2528/4885RAB9A 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.